Oral azithromycin for treatment of posterior blepharitis

Cornea

Volumn 30, Issue 10, 2011, Pages 1145-1149

  Igami, Thais Zamudio ^a,b   Holzchuh, Ricardo ^a,b   Osaki, Tammy Hentona ^b   Santo, Ruth Miyuki ^a   Kara Jose, Newton ^a   Hida, Richard Y ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

azithromycin; blepharitis; dry eye syndrome; macrolides; meibomian glands; tear instability

Indexed keywords

AZITHROMYCIN;

ADULT; ARTICLE; BLEPHARITIS; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; EYELID PRURITUS; FEMALE; HUMAN; HYPEREMIA; INTERVENTION STUDY; MALE; MEIBOMIAN GLAND; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TEAR FILM BREAK UP TIME; TEAR FLOW; TELANGIECTASIA;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BLEPHARITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; HYPEREMIA; MALE; MEIBOMIAN GLANDS; MIDDLE AGED; PROSPECTIVE STUDIES; PRURITUS; PULSE THERAPY, DRUG; TEARS; TREATMENT OUTCOME;

EID: 80052693962     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318207fc42     Document Type: Article

References (51)

1. Research in Dry Eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:179-193.
2. Gilbard JP. Dry eye, blepharitis and chronic eye irritation: divide and conquer. J Ophthalmic Nurs Technol. 1999;18:109-115.
3. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008;43:170-179. (Pubitemid 351518168)
4. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7: S1-S14.
5. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982;89:1173-1180. (Pubitemid 12003236)
6. McCulley JP, Shine WE. Changing concepts in the diagnosis and management of blepharitis. Cornea. 2000;19:650-658.
7. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996;40:343-367. (Pubitemid 26117272)
8. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol. 1995;113:1266-1270.
9. Barabino S, Rolando M, Chen L, et al. Exposure to a dry environment induces strain-specific responses in mice. Exp Eye Res. 2007;84:973-977. (Pubitemid 46613883)
10. Wieslander G, Norbäck D, Venge P. Changes of symptoms, tear film stability and eosinophilic cationic protein in nasal lavage fluid after reexposure to a damp office building with a history of flooding. Indoor Air. 2007;17:19-27. (Pubitemid 46174953)
11. McCulley JP, Shine W. A compositional based model for the tear film lipid layer. Trans Am Ophthalmol Soc. 1997;95:79-88; discussion 88-93.
12. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol. 2001;45(Suppl 2):S199-S202.
13. Kaido M, Dogru M, Ishida R, et al. Concept of functional visual acuity and its applications. Cornea. 2007;26:S29-S35. (Pubitemid 47442759)
14. Lemp MA. Evaluation and differential diagnosis of keratoconjunctivitis sicca. J Rheumatol Suppl. 2000;61:11-14.
15. Shimmura S, Shimazaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea. 1999;18:408-411. (Pubitemid 29294062)
16. Antonio JR, Pegas JR, Cestari TF, et al. Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety. J Dermatolog Treat. 2008;19:210-215.
17. Bakar O, Demircay Z, Yuksel M, et al. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol. 2007;32:197-200. (Pubitemid 46233028)
18. Singhi MK, Ghiya BC, Dhabhai RK. Comparison of oral azithromycin pulse with daily doxycycline in the treatment of acne vulgaris. Indian J Dermatol Venereol Leprol. 2003;69:274-276. (Pubitemid 39217101)
19. Akhyani M, Ehsani AH, Ghiasi M, et al. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47:284-288. (Pubitemid 351266852)
20. Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151-154. (Pubitemid 38256452)
21. Bakar O, Demircay Z, Toker E, et al. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol. 2009;23:544-549.
22. Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Arch Dermatol. 2004;140:489-490. (Pubitemid 38469260)
23. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 1997;36:239-240.
24. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000;39:45-50. (Pubitemid 30113541)
25. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother. 1998;41(Suppl B):37-46. (Pubitemid 28152222)
26. Sehgal VN, Sharma S, Sardana K. Rosacea/acne rosacea: efficacy of combination therapy of azithromycin and topical 0.1% tacrolimus ointment. J Eur Acad Dermatol Venereol. 2008;22:1366-1368.
27. Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010;29:781-788.
28. Haque RM, Torkildsen GL, Brubaker K, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29: 871-877.
29. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25:858-870.
30. Toda I, Tsubota K. Practical double vital staining for ocular surface evaluation. Cornea. 1993;12:366-367.
31. Hikichi T, Yoshida A, Fukui Y, et al. Prevalence of dry eye in Japanese eye centers. Graefes Arch Clin Exp Ophthalmol. 1995;233:555-558.
32. Tsubota K, Monden Y, Yagi Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol. 1999; 83:767-770. (Pubitemid 29324784)
33. Kaido M, Goto E, Dogru M, et al. Punctal occlusion in the management of chronic Stevens-Johnson syndrome. Ophthalmology. 2004;111: 895-900. (Pubitemid 38586681)
34. van Bijsterveld OP. Diagnostic tests in the sicca syndrome. Arch Ophthalmol. 1969;82:10-14.
35. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31:12-20. (Pubitemid 350236720)
36. Rubin BK. Immunomodulatory properties of macrolides: overview and historical perspective. Am J Med. 2004;117(Suppl 9A):2S-4S.
37. Voils SA, Evans ME, Lane MT, et al. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother. 2005;39:86-94. (Pubitemid 40052383)
38. Aronowicz JD, Shine WE, Oral D, et al. Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol. 2006;90:856-860. (Pubitemid 43973996)
39. Dougherty JM, McCulley JP, Silvany RE, et al. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991;32:2970-2975.
40. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003;76:417-420. (Pubitemid 36299053)
41. Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea. 2003; 22:545-548. (Pubitemid 36909734)
42. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc. 1999;74:613-634. (Pubitemid 29264782)
43. Gilmans GA. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Medical Publishing Division, 2006.
44. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292:156-163. (Pubitemid 30026366)
45. Levert H, Gressier B, Moutard I, et al. Azithromycin impact on neutrophil oxidative metabolism depends on exposure time. Inflammation. 1998;22: 191-201. (Pubitemid 28177176)
46. Tabbara KF, al-Kharashi SA, al-Mansouri SM, et al. Ocular levels of azithromycin. Arch Ophthalmol. 1998;116:1625-1628. (Pubitemid 29001960)
47. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol. 1984;68:524-528. (Pubitemid 15135457)
48. Groden LR, Murphy B, Rodnite J, et al. Lid flora in blepharitis. Cornea. 1991;10:50-53.
49. Dougherty JM, Osgood JK,McCulley JP. The role of wax and sterol ester fatty acids in chronic blepharitis. Invest Ophthalmol Vis Sci. 1991;32:1932-1937.
50. Souchier M, Joffre C, Gregoire S, et al. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol. 2008;92:819-822. (Pubitemid 351839576)
51. Modi S, Harting M, Rosen T. Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic. J Drugs Dermatol. 2008;7: 898-899.